Why Applied Materials Stock Hit A New 52-Week High Today

Applied Materials, Inc. (NASDAQ: AMAT) shares are trading higher by 4.63% to $152.90 Friday afternoon. Shares of semiconductor and chip stocks are trading higher after Intel Corporation and KLA Corp reported strong quarterly results.

Applied Materials, Inc. (NASDAQ:AMAT) shares are trading higher by 4.63% to $152.90 Friday afternoon. Shares of semiconductor and chip stocks are trading higher after Intel Corporation and KLA Corp reported strong quarterly results.

See Also: Intel’s Q2 Results Get Mixed Reactions From 4 Analysts: ‘AI Contribution Remains Modest’

What Happened With Intel?

Intel announced its second-quarter revenue of $12.9 billion, representing a 15% year-over-year decrease. The reported revenue exceeded the analyst consensus estimate of $10.97 billion. The company achieved earnings per share of 13 cents, outperforming the Street consensus estimate of a loss of 3 cents per share.

Intel CEO Pat Gelsinger expressed satisfaction with the second-quarter results, stating that they surpassed the high end of their guidance. He highlighted the successful execution of their strategic priorities, which includes gaining traction with their foundry business and delivering on their product and process roadmaps…Read More

According to data from Benzinga Pro, AMAT has a 52-week high of $153.28 and a 52-week low of $71.12.

Total
0
Shares
Related Posts
Read More

Lennar Shares In Building Mode: Behind The Earnings Beat And Rising Homebuilder Confidence

Lennar Corp (NYSE: LEN) shares are on the rise as the homebuilder's earnings outperformed expectations on both revenue and earnings per share. While this may be one factor driving the stock price, another catalyst could be the uptick in a separate homebuilder confidence indicator.

LEN

Read More

Anaptys Top-Line GEMINI-2 Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis; Patients Who Received A Single Dose Of 750mg IV Imsidolimab, 53% Achieved A GPP Physician Global Assessment Score Of 0/1 (Clear Or Almost Clear S…

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least

ANAB